Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital

Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital

BACKGROUND: Trastuzumab (Herceptin®, Roche) has significantly improved the prognosis of patients with HER2-positive metastatic breast cancer. Some patients remain in remission for many years. However, there are no prognostic markers associated with long-term survival. This study aimed to analyse t...

Full description

Bibliographic Details
Main Authors:	Lilian Bringolf, Bernhard Pestalozzi, Daniel Fink, Konstantin Dedes
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2016-12-01
Series:	Swiss Medical Weekly
Subjects:	anti anti-HER2-targeted treatment HER2 HER2-positive long long-term outcome
Online Access:	https://www.smw.ch/index.php/smw/article/view/2259

Similar Items

Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review
by: Michelle D. Hackshaw, et al.
Published: (2021-08-01)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
by: Eriko Tokunaga, et al.
Published: (2021-08-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
by: Bin Shao, et al.
Published: (2022-08-01)

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
by: Emanuela Ferraro, et al.
Published: (2021-08-01)

A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
by: Shuling Zhou, et al.
Published: (2023-01-01)

Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
by: M. A. Frolova, et al.
Published: (2021-12-01)

HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation
by: Martyna Zielińska, et al.
Published: (2020-06-01)

New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
by: Essia Mezni, et al.
Published: (2020-06-01)

Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
by: Manuel Gámez-Chiachio, et al.
Published: (2022-09-01)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
by: Simon Peter Gampenrieder, et al.
Published: (2021-12-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
by: Elizabeth Rubin, et al.
Published: (2024-01-01)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
by: Xiaohui Zhang, et al.
Published: (2021-08-01)

The Modified Neo-Bioscore System for Staging Breast Cancer Treated with Neoadjuvant Therapy Based on Prognostic Significance of HER2-Low Expression
by: Yingying Zhao, et al.
Published: (2024-03-01)

HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma
by: Lingli Chen, et al.
Published: (2022-02-01)

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
by: Iain R. Macpherson, et al.
Published: (2019-12-01)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
by: Patrik Pöschke, et al.
Published: (2023-09-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis
by: Marco Macagno, et al.
Published: (2022-01-01)

<i>HER2</i> and <i>BARD1</i> Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
by: Apolonia Novillo, et al.
Published: (2023-01-01)

Long-term survival in a patient with metastatic HER2+ breast cancer undergoing lapatinib-based therapy for 6 years
by: Salvatore Turano, et al.
Published: (2018-09-01)

Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data
by: Haizhu Chen, et al.
Published: (2023-11-01)

Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer
by: Huizi Lei, et al.
Published: (2023-06-01)

Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature
by: Jennifer Y. Ge, et al.
Published: (2021-07-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
by: Chiara Tommasi, et al.
Published: (2024-03-01)

Low-level expression of human Epidermal growth Factor Receptor-2 (HER2) in High-Grade Mullerian Tumors: Implications for therapy decision making
by: Evi Abada, et al.
Published: (2023-10-01)

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
by: Sabine Schmid, et al.
Published: (2019-09-01)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
by: Paula González-Alonso, et al.
Published: (2015-08-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions
by: Saleh Alrhmoun, et al.
Published: (2022-12-01)

Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis—The Adjuvant Role of Lifestyle Changes
by: Larisa Maria Badau, et al.
Published: (2022-03-01)

Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence
by: Kamel Debbi, et al.
Published: (2023-04-01)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
by: Liu Yang, et al.
Published: (2022-04-01)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
by: Marta Tapia, et al.
Published: (2023-09-01)

The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)
by: Fangfang Duan, et al.
Published: (2022-03-01)

Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition
by: Takuya Osada, et al.
Published: (2017-06-01)